Miguel Gallardo, researcher and coordinator of the H12O-CNIO Haematological Malignancies Clinical Research Unit headed by Joaquín Martínez at the Spanish National Cancer Research Centre (CNIO), has participated in a study ...
May 27, 2019
0
2
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern. It has often been assumed that drug resistance is due to the presence or development ...
May 15, 2019
0
14
Cells of certain blood cancers such as Hodgkin's lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the risk of their occurrence, ...
Apr 15, 2019
0
1
The scientific community has made great strides over the past decade in the development of a new class of cancer therapy called immunotherapy, a treatment that activates a patient's own immune system to target cancer cells. ...
Feb 14, 2019
0
38
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients ...
Dec 2, 2018
0
4
A novel immunotherapy appears safe for use in patients with a type of blood cancer called non-Hodgkin's lymphoma, according to a phase-1 multicenter clinical trial led by a researcher at the Stanford University School of ...
Oct 31, 2018
0
91
Self-reported quality of life among patients diagnosed with aggressive lymphoma can predict overall survival and event-free survival, a Mayo Clinic study has found. The results were presented at the 56th American Society ...
Jul 9, 2018
0
0
The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...
May 1, 2018
0
128
Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body's lymph nodes, which are connected to a network of lymph vessels ...
Apr 12, 2018
0
38
In a new study, researchers identified genetic subtypes of diffuse large B-cell lymphoma (DLBCL) that could help explain why some patients with the disease respond to treatment and others don't. The study, led by researchers ...
Apr 11, 2018
0
12
